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Abstract18
Heterocyclic aromatic amines (HCA) are carcinogenic mutagens formed during cooking 19
of proteinaceous foods, particularly meat. To assist in the ongoing search for 20
biomarkers of HCA exposure in blood, a method is described for the extraction from 21
human plasma of the most abundant HCAs: 2-Amino-1-methyl-6-phenylimidazo(4,5-22
b)pyridine (PhIP), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-23
3,4,8-trimethylimidazo[4,5-f]quinoxaline (4,8-DiMeIQx) (and its isomer 7,8-DiMeIQx),24
using Hollow Fibre Membrane Liquid-Phase Microextraction. This technique employs 25
2.5 cm lengths of porous polypropylene fibres impregnated with organic solvent to 26
facilitate simultaneous extraction from an alkaline aqueous sample into a low volume 27
acidic acceptor phase. This low cost protocol is extensively optimised for fibre length, 28
extraction time, sample pH and volume. Detection is by UPLC-MS/MS using positive 29
mode electrospray ionisation with a 3.4 min runtime, with optimum peak shape, 30
sensitivity and baseline separation being achieved at pH 9.5. To our knowledge this is 31
the first description of HCA chromatography under alkaline conditions. Application of 32
fixed ion ratio tolerances for confirmation of analyte identity is discussed. Assay 33
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precision is between 4.5 and 8.8% while lower limits of detection between 2 and 5 34
pg/mL are below the concentrations postulated for acid-labile HCA-protein adducts in 35
blood.36
37
38
Keywords:39
Heterocyclic aromatic amine, PhIP, MeIQx, Hollow fibre membrane liquid-phase 40
microextraction, Human plasma, UPLC-MS/MS.41
42
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1. Introduction43
44
Heterocyclic aromatic amines (HCAs) are formed during the cooking of proteinaceous 45
foods, particularly meat and fish, which provide creatin(in)e and other precursors such 46
as amino acids, sugars or other aldehydes [1]. Their formation in the parts per billion 47
concentration range is highly dependent upon the type of food and degree of cooking;48
therefore making estimation of dietary exposure to HCAs difficult [2]. The past 30 years 49
have seen extensive investigation into HCAs, in terms of their production, metabolism50
[3], formation of adducts with DNA [4] and protein [5], their quantification [6] and 51
implications for human health.52
53
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), 2-amino-3,8-54
dimethylimidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-3,4,8-trimethylimidazo[4,5-55
f]quinoxaline (4,8-DiMeIQx) (Fig. 1) are three of the most abundant HCAs present in 56
cooked meat and fish [7,8] although many others have been identified [9]. There is 57
strong evidence from animal and in vitro studies of the carcinogenic and mutagenic58
properties of the HCAs although in vivo evidence correlating HCA dietary intake and 59
incidence of cancers can be equivocal [10,11]. To overcome the limitations of 60
estimating HCA intake by food frequency questionnaires, direct measurement of the 61
HCAs, their metabolites or their DNA or protein adducts in vivo is necessary. The 62
methodology of analysis of PhIP and its metabolites has been reviewed by Teunissen 63
and colleagues [12] who concluded that LC-MS/MS was clearly the detection method of 64
choice for sensitive qualitative and quantitative analyses of this most abundant of HCAs65
in biological matrices. Sample pretreatment for HCA analysis usually involves protein 66
precipitation, liquid-liquid extraction (LLE) or solid phase extraction (SPE).67
68
Hollow Fibre Membrane Liquid-Phase Microextraction (HF-LPME) techniques, which 69
employ porous membrane fibres to support an organic solvent during extraction of an 70
aqueous sample, were first introduced by Pedersen-Bjergaard and Rasmussen in 199971
[13] and have received considerable attention for analyses of environmental 72
contaminants and pharmaceuticals and related substances in body fluids, as reviewed 73
by Lee and colleagues [14]. More widespread adoption of HF-LPME is possible, 74
particularly in combination with LC-MS/MS detection techniques [14]. The application of 75
HF-LPME techniques to extraction of HCAs has been limited, yet the traditional 76
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extraction methods for HCAs (usually LLE and/or SPE) are prime candidates for 77
transfer to HF-LPME techniques. HF-LPME was first applied to extraction of PhIP from 78
urine and plasma by a group in Lund University, Sweden [15] who then expanded this 79
to eleven HCAs [16] and metabolites of PhIP in urine [17], proposing urinary PhIP as a 80
possible biomarker of exposure to dietary PhIP [18]. This extraction technique has also 81
been applied to the detection of HCAs in barbecued meats [19].82
83
Despite considerable research into the fate of HCAs in vivo, with much now focussing 84
on adducts to DNA, a reliable marker for HCA exposure (either circulating free or 85
adducted to blood proteins such as serum albumin or haemoglobin) remains elusive.86
There is a need for further validated HCA extraction techniques from blood products to 87
assist in this search.88
89
The three-phase HF-LPME system [14] described in the current study uses a porous 90
polypropylene hollow fibre impregnated with a small volume of organic solvent (the91
supported liquid membrane phase). An acidic aqueous acceptor phase fills the lumen of 92
the hollow fibre. The third phase is the alkaline aqueous sample (donor phase) 93
containing the weakly basic HCA analytes into which the fibre is immersed. Extraction is 94
by diffusion based on pH differences an  is effectively a simultaneous double liquid-95
liquid extraction from alkaline sample to organic phase to acidic acceptor phase.96
97
Hollow fibres require preparation by the operator prior to use. We have noted that the 98
literature employing hollow fibres for extractions from low volume biological samples 99
does not always provide clear descriptions of the procedures involved. Therefore, in the 100
current study we have focussed on some of the detailed practicalities of preparing and 101
handling hollow fibres in addition to the optimisation and validation of the extraction 102
protocol and LC-MS/MS detection of HCAs in human plasma.103
104
2. Materials and methods105
106
2.1. Reagents and samples107
Reference standards 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-108
amino-3,8-dimethyl-imidazo [4,5-f]quinoxaline (MeIQx), 2-amino-3,4,8-trimethylimidazo109
[4,5-f]quinoxaline (4,8-DiMeIQx), 2-amino-3,7,8-trimethylimidazo [4,5-f]quinoxaline (7,8-110
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DiMeIQx) and deuterium labelled internal standards (I.S.) D3-PhIP, D3-MeIQx and D3-111
4,8-DiMeIQx were obtained from Toronto Research Chemicals (North York, ON, 112
Canada). Mixed standard solutions prepared in LCMS grade methanol were stored at 113
4°C. Unless stated, all other chemicals were obtained from Sigma-Aldrich (Dorset, UK).114
115
Blood samples, obtained from the research project FoodCAP funded by the World 116
Cancer Research Fund (Grant ID 2010/255), were from healthy volunteers who had 117
fasted for 10-12 h to ensure removal of free circulating HCAs from serum. This study 118
was conducted according to the guidelines laid down in the declaration of Helsinki and 119
all procedures involving human subjects were approved by the School of Medicine,120
Dentistry and Biomedical Sciences Research Ethics Committee of Queen’s University 121
Belfast. Each participant provided written, informed consent prior to blood donation.122
123
2.2. Apparatus124
Accurel® PP 300/1200 polypropylene hollow fibre membranes (300 μm wall thickness, 125
1200 μm inner diameter and 0.2 μm pore size, F-No-5129, manufactured by Membrana 126
GmbH, Wuppertal, Germany) were kindly donated by the Danish Meat Research 127
Institute (Roskilde, Denmark). Sample extractions were carried out in LC-GC certified 128
clear glass 2 ml HPLC microvials (12 x 32 mm) with screw neck caps containing 129
bonded pre-slit PTFE/silicone septa obtained from Waters Corporation (Manchester, 130
UK), and also used 18 gauge by 2.5 cm (0.8 mm needle outer diameter) syringe 131
needles (Sigma Aldrich) and 8 x 3 mm PTFE stirrer magnets (Scientific Laboratory 132
Supplies, Nottingham, UK).133
134
An Acquity I-class UPLC® binary pump and sample management system (Waters 135
Corporation, Man hester, UK) coupled to a Xevo TQS tandem mass spectrometer 136
(Waters Corporation), both controlled by MassLynx™ software, were used for sample 137
extract analysis. The mass spectrometer operated under positive electrospray 138
ionisation mode (ESI). Data acquisition was in Multiple Reaction Monitoring mode 139
(MRM) with a total run time of 3.4 min. Data analysis was performed using Waters 140
TargetLynx™ software. MS source settings were as follows: capillary voltage 0.5 kV,141
source temperature 150°C, desolvation temperature 650°C, cone nitrogen gas flow 150 142
L/h, desolvation nitrogen gas flow 1000 L/h. Separation of HCAs was carried out on an 143
Acquity BEH C18 1.7 m UPLC analytical column (50 x 2.1 mm) equipped with an in-144
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line filter unit (0.2 µm, 2.1 mm) (Waters Corporation), maintained at 40°C. A binary 145
gradient mobile phase was applied at a flow rate of 0.8 mL/min, phase A being 5 mM 146
ammonium formate pH 9.5 (aq) and phase B being acetonitrile. The rapid gradient 147
profile was: (1) 0-0.2 min, held at 93% A, (2) 0.2-2 min, falling linearly to 75% A, (3) 148
2.01-2.2 min, held at 70% A, (4) 2.25-2.75 min, held at 50% A, (5) 2.8-3.4 min, held at 149
93% A. The UPLC purge wash was acetonitrile:water (10:90, v/v) and the wash solution150
was acetonitrile:water (50:50, v/v). Injection volume was 5 µl. Table 1 provides details of 151
HCA fragmentation transitions and other MS/MS conditions.152
153
2.3. Preparation of hollow fibres154
The optimised conditions for extraction of HCAs from plasma using HF-LPME are 155
described below. Description of the method optimisation study follows in section 2.6. 156
Porous Accurel® PP 300/1200 polypropylene hollow fibre membranes were cut into 2.5157
cm lengths and one end was heat-sealed using a hot soldering iron – the fibre tip was158
touched lightly onto the hot iron surface for 1-2 sec and then immediately squeezed159
repeatedly using fine tipped metal tweezers to form a seal of approximately 3-4 mm160
length. The fibre was cleaned by soaking in acetone for 10 min before drying at 37°C161
for approximately 15 min (in a glass or paper container, not plastic, to avoid damage by 162
residual acetone). Sealed fibres were stored in a capped glass tube prior to use. If 163
condensation of acetone is evident during storage, fibres should be re-dried at 37°C. 164
Immediately prior to use, fibres were prepared for extraction by filling the lumen of the 165
hollow fibre with acidic acceptor phase and filling the pores of the fibre membrane with 166
organic solvent as follows. An 18 gauge hypodermic needle fitted to a 1 mL disposable 167
plastic syringe containing acidic acceptor solution (0.1 M sulphuric acid) was inserted 168
carefully into the unsealed end of the fibre ensuring the membrane was not punctured 169
and a strong seal was achieved (use of a fibre with different internal diameter would 170
require a different gauge needle). Acceptor solution was injected firmly into the lumen of 171
the fibre until droplets were clearly visible on the outer surface of the porous fibre and 172
no leakage was evident from the sealed end. The fibre was removed from the needle173
and a clean hypodermic needle protruding through the pre-slit septum of a microvial 174
screw cap was carefully inserted. Holding the needle Luer-Lok connector, the fibre was175
then dipped into 1-octanol for 30 sec, allowing the organic solvent to fill the membrane176
pores. Excess 1-octanol on the fibre surface was removed by manually shaking the 177
fibre in deionised 18Ω water for 30 sec. The prepared fibre could then be conveniently 178
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immersed in a sample vial, allowing the screw cap to be sealed and the height of the 179
fibre adjusted through the pre-slit septum without removing or touching the fibre. Each 2180
mL sample vial contained an 8 x 3 mm stirrer magnet and the needle height was 181
adjusted to avoid the stirrer damaging the sealed end of the fibre during extraction (Fig. 182
2).183
184
2.4. Sample extraction185
Plasma samples (0.2 mL) were placed in 2 mL glass HPLC microvials and fortified with 186
50 pg/mL internal standard (I.S.; 10 µl of 1 ng/mL mixed deuterium labelled HCAs D3-187
PhIP, D3-MeIQx and D3-4,8-DiMeIQx) for validation and routine analyses. For 188
optimisation of the method the I.S. were added to samples after extraction by addition 189
of 10 µl to the HPLC microvial insert containing the recovered acidic acceptor phase to 190
enable calculation of HCA extraction efficiency. For optimisation and validation of the 191
method, mixed standard HCAs were added to samples prior to extraction at 30 pg/mL192
(60 µl of 100 pg/mL mixed PhIP, MeIQx, 7,8-DiMeIQx and 4,8-DiMeIQx). Samples were 193
made alkaline by addition of 1.3 mL of 0.5 M NaOH and a 8 x 3 mm stirrer magnet was194
placed in each microvial. A prepared hollow fibre was immersed in each sample as 195
described above (Fig. 2) and vials were placed in a Perspex microvial rack on a single 196
position magnetic stirrer at room temperature for 5 h, stirring at 550 rpm. Use of a 197
microvial rack avoided the need for a multiple-position magnetic stirrer. After extraction 198
the fibre was removed from the sample with the needle still attached. The fibre sealed 199
end was cut off with sharp scissors and an air filled 1 mL disposable syringe used to 200
expel the acceptor phase (typically 20 µl from a 2.5 cm fibre) into a pre-weighed 200 µl 201
glass insert inside a 2 mL HPLC microvial. The recovered liquid was weighed and an 202
equal volume of 0.1 M NaOH was added to neutralise the acidic accepter phase. The 203
neutralised extract was then made up to a final volume of 100 µl by addition of 30 mM 204
ammonium formate (aq.) pH 9.5 to ensure compatibility with the LC-MS/MS mobile 205
phase.206
207
2.5. Calibration208
LC-MS/MS solvent calibration standards were prepared by addition of I.S. and 209
increasing volumes of 100 pg/mL mixed standard HCAs in microvials. Solvent was 210
evaporated to dryness under nitrogen and standards were reconstituted in 20 µl 211
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acetonitrile and 80 µl of 30 mM ammonium formate pH 9.5 before transferring to 200 µl 212
glass microvial inserts.213
214
2.6. Method optimisation215
The optimum conditions for extraction using HF-LPME are highly dependent upon the 216
target compound and the fibre being used. Each new extraction method requires217
specific optimisation to take account of the structure of the analytes and the gauge of 218
fibre employed. The critical variables assessed in this optimisation study were the 219
length of hollow fibre, the molarity of NaOH used to dilute the plasma sample, the final 220
volume of diluted sample and the extraction time. The four HCA analytes being 221
extracted from plasma included three compounds based on an imidazo-quinoxaline 222
skeleton (MeIQx, 4,7-DiMeIQx, 7,8-DiMeIQx) and one based on a phenyl-imidazo-223
pyridine skeleton (PhIP). Plasma from a single volunteer was used during method 224
optimisation. Plasma was fortified with HCAs prior to extraction under various 225
conditions (duplicate samples for each condition) and I.S. added after extraction.226
227
2.7. Method validation228
Validation of the optimised extraction method was carried out using plasma from a 229
single volunteer, seven aliquots being fortified with 30 pg/mL HCA  mixed standards 230
and 50 pg/mL I.S. prior to extraction on each of 3 days. Extracted HCAs were quantified 231
against solvent calibration curves. Plasma fortified with I.S. only was included as a 232
negative control. Samples fortified with progressively lower HCA concentrations were 233
extracted in order to estimate limits of detection and quantification.234
235
236
3. Results and discussion237
238
Development of this HF-LPME technique demonstrated the convenience of leaving the 239
hollow fibre attached to a hypodermic needle during extraction, allowing easy handling 240
and recovery of acceptor phase when extracting a limited sample volume. The fibre 241
need not be touched after immersion in the sample as the needle Luer-Lok acts as a 242
convenient handle for the remainder of the procedure. Other authors have immobilised 243
the fibre on a wire during extraction [17], however this requires the fibre to be 244
transferred after extraction from the wire to a new needle for recovery of the acceptor 245
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phase, increasing the number of handling steps and the risk of cross-contamination. For 246
larger liquid sample volumes, a longer fibre may be used and both ends sealed before 247
complete immersion of the fibre in the sample without any support. This approach has 248
been used at the University of Seville for extraction of pharmaceuticals from urine and 249
environmental water samples [20,21]. The use of HPLC microvials with pre-slit septa 250
screw caps as sample containers proved to be a simple way to secure the fibres and 251
needles during extraction and a convenient way to adjust fibre depth in the sample. 252
Acceptor phase could even be recovered from the fibre without removing the needle 253
from the pre-slit septum. A little practice in preparation of the fibres, particularly the 254
sealing of the ends with a soldering iron, yielded consistent results, with less than 5% of 255
fibres leaking from the sealed end when filling with acceptor phase (these fibres were 256
discarded).257
258
3.1. Method optimisation259
260
3.1.1. LC-MS/MS optimisation261
Several sub-2 µm, octadecylsilyl (C18-based) UPLC columns manufactured by Waters 262
were assessed for the separation of the four HCAs (HSS T3, HSS, BEH C18, CSH C18263
and AccQTag Ultra) in addition to a Phenomenex Kinetex pentafluorophenyl (PFP, 2.6264
µm) column. All were assessed under acidic mobile phase A conditions ranging from 265
pH 3.5 to 6.4, while BEH C18 and Kinetex PFP were also assessed at alkaline pH 8.0 266
to 9.5. Notably, the BEH column yielded the best peak shape, sensitivity (peak 267
intensity) and baseline separation of the DiMeIQx isomers at pH 9.5 - the natural pH of 268
5 mM ammonium formate, avoiding the need for pH adjustment of mobile phase A (Fig. 269
3). Separation of HCAs has traditionally been achieved under acidic LC conditions 270
[1,12], on the principle that mobile phase pH should be lower than the analyte pKa (<pH 271
5 for the HCAs) in order to fully protonate the HCA amine groups prior to positive mode 272
electrospray ionisation. However, baseline chromatographic separation of the DiMeIQx 273
isomers is sensitive to pH and is incomplete under the commonly used pH 4.7 or lower 274
[22,16]. Holland and colleagues [23] unusually employed a mobile phase ranging from 275
pH 6.8 to 7.85 to separate HCAs, including 4,8-DiMeIQx, in hydrolysed urine but the 276
degree of chromatographic separation from 7,8-DiMeIQx was not described. In the 277
current study, use of pH 9.5 and the UPLC gradient described above (5mM aqueous 278
ammonium formate and acetonitrile) facilitated baseline separation of MeIQx (tR 1.07279
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min), 7,8-DiMeIQx (1.31 min), 4,8-DiMeIQx (1.38 min) and PhIP (2.21 min) with a total 280
gradient runtime of 3.4 min and typical peak widths of 3.4-3.8 sec (Fig. 4). Ammonium 281
formate was employed as an ion pairing agent, in keeping with Bianchi and colleagues282
[24] who demonstrated better HCA peak shapes with formate than with acetate. It may 283
be that investigators, on observing improved HCA peak shape as mobile phase pH was 284
lowered below pH 4.7, have not previously studied the benefits of LC conditions closer 285
to or higher than neutral. Nevertheless, as stated by Bianchi and colleagues [24], 286
“depending on the specific purpose and design of the experiment, fine adjustments for 287
pH and mobile phase concentration are always recommended to achieve optimal 288
separation of HCAs”. To our knowledge this is the first report of chromatographic 289
separation of HCAs under alkaline LC-MS/MS conditions. The benefits of alkaline 290
mobile phase conditions with positive mode ionisation are clearly compound dependent, 291
as shown by Gerssen and colleagues [25] who observed improved recovery from 292
shellfish of the marine toxin azaspiracid-1 using pH 11 LC conditions compared with pH293
2.6 under positive ESI, attributing this to altered matrix suppression effects, whilst other 294
toxins performed better under acidic conditions. Kipper and colleagues [26] also found 295
that optimum signal intensities and peak separation of several antibiotics under positive 296
ESI were achieved at pH 9.297
298
The choice of fragmentation transitions for identification of the isomers of DiMeIQx is 299
important. Both 4,8-DiMeIQx and 7,8-DiMeIQx share m/z 228>213 as their most intense 300
transition. In the absence of demonstrable chromatographic separation, studies which 301
use this peak for quantification of DiMeIQx (for example [23,27]) risk misidentification of 302
the isomers. It is advisable to use the m/z 213 fragment as the qualitative (confirmatory)303
ion and to use the less intense, but essentially unique, fragments m/z 212 and m/z 131 304
for reliable quantification of 4,8-DiMeIQx and 7,8-DiMeIQx respectively (Table 1 and 305
Fig. 4).306
307
3.1.2. Fibre length optimisation308
The bar charts in Fig. 5 illustrate the proportion of HCAs extracted under various 309
conditions from plasma fortified with 30 pg/ml mixed HCAs. Data are normalised to 310
percentages of the maximum HCA concentration extracted under the assessed 311
conditions. HF-LPME extraction conditions were as described above in sections 2.3 and 312
2.4, with each of the following four variables being independently optimised.313
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314
Fig. 5a demonstrates the influence of the length of hollow fibre used in a fixed sample 315
donor volume of 1.5 ml, with 0.5 M NaOH diluent and 5 h extraction time. A 1 cm length 316
of fibre clearly provided insufficient acidic acceptor phase for successful extraction (8-317
14 µl recovered) due to loss of lumen volume following sealing of the fibre and insertion 318
of the supporting needle. A 2.5 cm length was convenient for the 2 ml HPLC vials. 319
Using a pair of 2.5 cm fibres in a single sample vial yielded twice the volume of 320
acceptor phase following extraction (45 µl) but only a marginal increase in PhIP and 321
MeIQx recovery and required twice the time and consumable materials to prepare. 322
Longer fibres had a detrimental effect on MeIQx recovery and had to be folded once or 323
twice to be fully submerged in the sample, risking damage to the integrity of the 324
supported organic layer during extraction. Therefore, a single 2.5 cm fibre was used for 325
all further extractions.326
327
3.1.3. Donor NaOH molarity optimisation328
Fig. 5b demonstrates that HCA extraction efficiency by HF-LPME is influenced by the 329
molarity of NaOH used to create the alkaline sample conditions for extraction (0.2 ml 330
plasma sample was diluted with 1.3 ml NaOH). At least 0.5 M NaOH was required to 331
achieve maximum analyte recovery (1 M in the case of MeIQx) with extraction efficiency 332
dropping when more concentrated NaOH was used. This is in contrast to Busquets and 333
colleagues [17,18] who suggested that PhIP or its metabolites could be extracted from 334
urine using HF-LPME with greater signal to noise ratio when mildly acidic conditions 335
were employed (pH 5.5) compared with a donor pH greater than 10. However, this 336
observation was not consistent across Busquets’ studies. It is also in contradiction of 337
the conventional use of alkaline sample conditions for the extraction of a weakly basic 338
compound such as PhIP (pKa=5.6) into an organic solvent followed by back-extraction 339
into an acidic acceptor phase [15]. Furthermore, the current study shows that simply 340
raising sample pH above 10 may not be optimal for HCA extraction. Observed pH in 341
duplicate diluted plasma samples prior to extraction were as follows: 0.01 M NaOH (pH 342
11.0), 0.05 M (pH 12.5), 0.2 M (pH 13.2), 0.5 M NaOH (pH 13.5), 1 M (pH 13.6) and 2343
M (pH 13.7). It can be seen from Fig. 5b that even at sample pH 12.5 (0.05 M NaOH), 344
extraction of HCAs may still be less than 50% of maximum. A NaOH molarity of 0.5 M 345
(pH 13.5) was employed as a compromise for the optimal extraction of the quinoxaline 346
and pyridine HCAs. The use of 0.5 M NaOH is in agreement with the studies of HCA 347
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extraction from urine by HF-LPME emanating from Lund University, Sweden 348
[15,16,17,18]. However, low parts per billion concentrations of PhIP and 4,8-DiMeIQx 349
were also successfully extracted from cooked meats by HF-LPME using 0.05 M NaOH 350
[19], although extraction efficiency was not described.351
352
3.1.4. Donor volume optimisation353
Fig. 5c illustrates the influence of the final volume of a 0.2 ml plasma sample diluted 354
with 0.5 M NaOH prior to extraction using a 2.5 cm hollow fibre. Donor volume did not 355
influence the volume of acidic acceptor phase recovered (typically 22 µl from a 2.5 cm 356
fibre) but the dilution effect on the sample resulted in poorer extraction into the fixed 357
acceptor phase volume. A final donor volume of 1.5 ml was chosen as optimum for the 358
current system.359
360
3.1.5. Extraction time optimisation361
Fig. 5d illustrates how optimum extraction time using HF-LPME is dependent upon the 362
chemical characteristics of the analytes. PhIP (a phenyl-imidazo-pyridine) reached 363
maximum recovery after 5 h, while the three imidazo-quinoxaline compounds extracted 364
more slowly, with recovery still rising after 7 h. A compromise protocol of 5 h was 365
adopted to cover all analytes and to facilitate completion of a sample batch extraction 366
within a single working day.367
368
This 5 h extraction time is in keeping with Ramos Payan and colleagues [20] who 369
extracted fluoroquinolone antibiotics from bovine urine and environmental water 370
samples in a 5.5 h timescale using HF-LPME. The same research group similarly 371
extracted sulphonamide antibiotics from human urine in 6 h, but extraction of non-372
steroidal anti-inflammatory drugs was achieved within 20 min [21], illustrating again the 373
need to optimise HF-LPME techniques for each analyte of interest. A review of 374
environmental and bioanalytical applications of HF-LPME [14] also highlighted the 375
variable extraction times and recoveries achievable by this technique, depending upon 376
analyte chemistry and sample type. Extraction times were often 1 h or less, but 377
recoveries were consequently incomplete.378
379
380
381
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3.2. Method validation382
Solvent calibration curves were linear in the range equivalent to 5-80 pg/mL plasma383
(10-160 pg/mL reconstitution solvent, or 50-800 fg on-column), coefficients of 384
determination R2 typically being greater than 0.998 for all HCAs. The mean recovery 385
and precision of the HF-LPME extraction method are shown in Table 2. Data are based 386
on 21 replicates of human plasma fortified with 30 pg/mL HCAs prior to extraction (7 387
replicates extracted on each of 3 days). Mean observed HCA concentrations (recovery) 388
were greater than 92% of fortified concentrations for all four HCAs. Precision (RSD) 389
was below 9% in all cases, both within and between runs, demonstrating satisfactory 390
performance at physiologically relevant HCA-adduct concentrations in human blood [28,391
29]. Estimated lower limits of detection and quantification based on signal-to-noise 392
ratios greater than 3 and 10 respectively (using Peak-to-Peak calculations on 393
unsmoothed raw data) in plasma fortified with HCAs prior to extraction are shown in 394
Table 2. Limits are based on the lowest intensity peak for each analyte. Limits for PhIP 395
are higher than for the quinoxaline HCAs due primarily to the low intensity of the 396
secondary, confirmatory transition peak for PhIP (m/z 225.2>183.2). HF-LPME assay 397
sensitivity and performance are similar to those reported by Lezamiz and colleagues 398
[15] who studied only PhIP in plasma. 399
400
Confidence in the identification of analytes is important when measuring low 401
concentrations of compounds in complex biological matrices, particularly for analyte 402
groups like the HCAs which share common structures and fragmentation patterns. The 403
presence of a second transition peak to confirm analyte identity should be a 404
prerequisite, although this is not always the case in the published literature of HCAs. 405
Furthermore, in the present study the ratio of confirmatory to primary quantitation peaks406
(ion ratio) was monitored in every sample to ensure agreement with the same ratio in 407
calibration standards. Guidance on the tolerances to apply to compliance of ion ratios 408
with their standards was taken from the document laying out the required analytical 409
performance of methods in the veterinary pharmaceuticals field: Commission Decision410
2002/657 [30]. While this European Commission document sets out to ensure animal-411
derived food products are free of harmful residues and is not directly applicable to the 412
study of natural carcinogens such as the HCAs, it is the opinion of the authors that 413
similar performance criteria should be applied to analysis of suspected carcinogens 414
whenever possible. Consequently, we applied the tolerances as defined in Decision 415
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2002/657 to the ion ratios in all samples: if ion ratios did not agree with the same ratios 416
in calibration standards to within 20 to 30% (dependent on the magnitude of the ratio), 417
the identity of the analyte peak could not be confirmed. Ion ratios greater than 0.5 are 418
permitted a tolerance of ±20% relative to calibration standards, 25% tolerance is 419
applied for ratios between 0.2 and 0.5, 30% for ratios of 0.1-0.2, and 50% for ratios 420
below 0.1. For example, the ratio of the peak areas of MeIQx daughter ions 131.1/199.1 421
(Table 1) was typically around 0.4, permitting this ratio in a sample to be within 25% of 422
the mean ratio of the same peaks in calibration standards.423
424
3.3. Application to blood samples425
Preliminary studies demonstrated that the HF-LPME plasma extraction method may 426
also be applied to serum and whole blood, although whole blood matrix effects caused 427
an additional 30-40% signal suppression and quantitative accuracy was adversely 428
affected, with I.S.-corrected recoveries being around 85% for the quinoxaline HCAs and 429
around 72% for PhIP (data not shown), compared with 93-99% and 92% respectively in 430
plasma (Table 2).431
432
Human plasma samples were obtained from the World Cancer Research Fund project 433
FoodCAP. Samples were from volunteers whose dietary HCA intake was estimated434
using WISP nutritional analysis software on the basis of 7 day food diaries and the US 435
National Cancer Institute’s CHARRED database436
(http://dceg.cancer.gov/tools/design/charred). Volunteers fasted for 10-12 h before 437
providing blood samples to ensure removal of free circulating HCAs from their plasma. 438
Unsurprisingly, no HCAs were detected in these samples using the optimised HF-LPME439
extraction method, even from volunteers with a nominally high HCA intake of greater 440
than 1 µg/day.441
442
Adducts of HCAs bound covalently to blood proteins such as haemoglobin and serum 443
albumin have, since the 1990s, been proposed as potential biomarkers of exposure to 444
HCAs (as reviewed by [2,31]). However, the suitability of protein adducts as reliable 445
indicators of potential carcinogenic damage by HCAs is still unproven [31].446
Furthermore, Magagnotti and colleagues [29] detected PhIP released by mild acid 447
hydrolysis from purified haemoglobin and serum albumin, demonstrating differences 448
between meat consumers and vegetarians in the range 7-67 pg/mL for PhIP-albumin 449
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adducts. However, this work has not been replicated since, despite ongoing studies in 450
the field.451
452
The current HF-LPME method was applied to plasma samples from high dietary HCA 453
intake volunteers in an attempt to measure protein-bound HCAs following their release 454
by the acid hydrolysis protocol of Magagnotti and colleagues [29]. Plasma was diluted 455
to a final concentration of 0.1 M hydrochloric acid and incubated at 80°C for 1 h before 456
adjusting the pH with NaOH and extracting by HF-LPME as described above. No acid-457
labile HCAs were detected under these conditions, demonstrating the need for further 458
work on the release of labile HCA adducts from blood proteins.459
460
461
4. Conclusions462
463
The described HF-LPME method presents a convenient and low cost technique for 464
extraction of carcinogenic heterocyclic aromatic amines from plasma. LC-MS/MS assay 465
sensitivity is in the range postulated for acid-labile HCA-protein adducts in blood [29], 466
with satisfactory assay precision and recovery. The hollow fibre membrane liquid-phase467
microextraction technique benefits from very low organic solvent usage compared with 468
conventional liquid-liquid extraction (LLE) and low cost compared with solid phase 469
extraction methods (SPE). To our knowledge this is the first description of a validated 470
HF-LME protocol for extraction of a group of HCAs from plasma and also of their 471
chromatographic separation under alkaline conditions.472
473
Extensive optimisation of the HF-LPME protocol demonstrates the need for such 474
microextraction techniques to be carefully optimised for each analyte of interest. A final 475
compromise protocol is described, balancing the variable recoveries between different 476
analytes and enabling a batch of approximately 20 samples to be completed in a 477
normal working day. It should be noted that samples can be left unattended during the 478
lengthy HF-LPME extraction step, freeing the operator for other duties, unlike manual 479
LLE and SPE techniques. This technique represents an additional, low cost extraction 480
tool in the ongoing search for biomarkers of exposure to carcinogenic heterocyclic481
aromatic amines in plasma.482
483
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589
FIGURE CAPTIONS590
591
Fig. 1. Structures of heterocyclic aromatic amines.592
593
594
Fig. 2. Format of hollow fibre membrane liquid-phase microextraction vials (2.5 cm 595
sealed fibre, 18 gauge needle, pre-slit septum cap and 1.5 mL diluted sample with 8 596
mm magnetic stirrer in 2ml microvial).597
598
599
Fig. 3. ESI-UPLC-MS/MS MRM chromatograms of primary quantitation peaks of 4,8-600
DiMeIQx and 7,8-DiMeIQx (eluting first from a 5cm BEH C18 UPLC column) illustrating 601
the beneficial effects on peak shape, sensitivity and baseline separation of increasing 602
mobile phase pH. Analyte m/z transitions and peak heights are listed.603
604
605
Fig. 4. ESI-UPLC-MS/MS MRM chromatograms of primary quantitation peaks of 606
heterocyclic aromatic amines and their deuterated internal standards extracted by HF-607
LPME from human plasma fortified at 30 pg/mL (I.S. at 50 pg/mL). Baseline separation 608
of DiMeIQx isomers is achieved at pH 9.5. Analyte names, m/z transitions and peak 609
heights are listed.610
611
612
Fig. 5. Optimisation of the extraction of four heterocyclic aromatic amines from plasma613
by hollow fibre membrane liquid-phase microextraction. Data are means of duplicate 614
extractions of plasma fortified at 30 pg/mL. Four HF-LPME variables were optimised -615
A: length of hollow fibre, B: molarity of NaOH diluent, C: donor (final sample) volume,616
and D: extraction time.617
618
619
620
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Optimised extraction of heterocyclic aromatic amines from blood using hollow fibre 
membrane liquid-phase microextraction and triple quadrupole mass spectrometry 
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Highlights 
 
 A Hollow Fibre Liquid Microextraction technique for heterocyclic amines is 
described. 
 HF-LPME extraction of carcinogenic HCAs from plasma is extensively 
optimised. 
 Optimum UPLC-MS/MS chromatography and positive mode ES ionisation 
achieved at pH 9.5. 
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Table 1 
Heterocyclic aromatic amine UPLC-MS/MS fragmentation conditions. 
Analyte 
tR (min) 
Primary 
transition (m/z) 
Confirmatory 
transition (m/z) 
Collision energy 
(V) 
PhIP 2.21 225.2>210.1 225.2>183.2 26 / 28 
   D3-PhIP 2.21 228.2>210.1 - 28 
MeIQx 1.07 214.2>199.1 214.2>131.1 24 / 36 
   D3-MeIQx 1.07 217.1>199.2 - 26 
7,8-DiMeIQx 1.31 228.2>131.1 228.2>213.1 36 / 24 
4,8-DiMeIQx 1.38 228.2>212.0 228.2>213.1 35 / 26 
   D3-4,8-DiMeIQx 1.38 231.2>213.1 - 24 
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Table 2 
Validation of HCA extraction by HF-LPME from plasma fortified with 30 pg/mL HCAs (n=21; 
7 replicates on 3 days). 
 PhIP MeIQx 7,8-DiMeiQx 4,8-DiMeIQx 
Mean concentration (pg/mL) 27.6 29.8 27.8 28.4 
Mean recovery (%)a 92.0 99.4 92.5 94.6 
Mean within day RSD (%) 5.4 4.5 6.4 7.1 
Between day RSD (%) 7.5 4.6 7.7 8.8 
Limit of detection (pg/mL) 5 3 2 2 
Limit of quantification (pg/mL) 15 10 7 7 
a
 I.S.-corrected recovery 
 
Table 2 Cooper
